Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Atrial fibrillation burden not reduced by XEN-D0103 in patients with pacemakers

March 12, 2018

CSL-112 found safe in patients with renal impairment after AMI

March 12, 2018

BC-007 reduces autoantibodies against G-protein coupled receptors in phase I study

March 12, 2018

MyoKardia reports Cohort B data from phase II PIONEER-HCM study of mavacamten

March 9, 2018

Pivotal phase III study of bempedoic acid in ASCVD meets primary endpoint

March 8, 2018

Caladrius Biosciences acquires license to late-stage CD34+ cell therapy program from Shire

March 8, 2018

Enrollment begins in phase I study of treprostinil Technosphere

March 6, 2018

Patient enrollment ongoing in AstraZeneca's phase II study of AZD-8601

March 2, 2018

First infant treated in Longeveron's mesenchymal stem cell therapy trial

March 2, 2018

DRP1 inhibitor mdivi-1 improves outcomes after experimental cardiac arrest

March 1, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...